Medigen Vaccine Biologics Balance Sheet Health
Financial Health criteria checks 5/6
Medigen Vaccine Biologics has a total shareholder equity of NT$3.8B and total debt of NT$1.7B, which brings its debt-to-equity ratio to 44.4%. Its total assets and total liabilities are NT$6.1B and NT$2.2B respectively.
Key information
44.4%
Debt to equity ratio
NT$1.71b
Debt
| Interest coverage ratio | n/a |
| Cash | NT$3.76b |
| Equity | NT$3.85b |
| Total liabilities | NT$2.25b |
| Total assets | NT$6.09b |
Financial Position Analysis
Short Term Liabilities: 6547's short term assets (NT$4.4B) exceed its short term liabilities (NT$2.0B).
Long Term Liabilities: 6547's short term assets (NT$4.4B) exceed its long term liabilities (NT$254.4M).
Debt to Equity History and Analysis
Debt Level: 6547 has more cash than its total debt.
Reducing Debt: 6547's debt to equity ratio has increased from 32.5% to 44.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6547 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 6547 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 7.4% each year